How China’s Drug Marketing Authorization Holder (MAH) System Unlocks Market Access for Foreign Biotechs
China’s Drug Marketing Authorization Holder (MAH) system, rolled out nationwide in 2019 under the revised Drug Administration Law, fundamentally restructured pharmaceutical liability. Instead of tying approval to a specific manufacturing license, the MAH system establishes a clear legal separation between the entity that owns the drug (the MAH) and the entity that makes the drug. For foreign biotechs launching an innovative asset, the MAH system eliminates the historical requirement to either build a local factory or completely transfer your technology to a local partner. Over 1,200 drug applications utilized this pathway in 2023 alone, representing a sharp rise from just 300 in 2020.
This FAQ addresses how foreign biotech executives can leverage the MAH structure to reduce capital expenditure, accelerate timelines, and maintain control over their intellectual property while navigating China’s evolving regulatory environment.
How the MAH System Changes the Business Model for Foreign Biotechs
Under the traditional model (pre-2019), a foreign company seeking to market a drug in China was effectively forced to build a local manufacturing facility or form a deeply integrated joint venture. This required a capital commitment of $10–50 million USD and a timeline of 3–4 years just to become operational. The new 药品上市许可持有人 (Drug Marketing Authorization Holder, yàopǐn shàngshì xǔkě chíyǒu rén) system removes this barrier.
The MAH model allows a foreign biotech to retain ownership of the drug license while contracting all manufacturing to a qualified 合同生产组织 (Contract Manufacturing Organization, hétong shēngchǎn zǔzhī). This “asset-light” approach reduces initial capital commitment by up to 60% and cuts time-to-market by an average of 12–18 months. In a market where first-mover advantage can determine a drug’s peak revenue trajectory, this speed is transformative.
| Feature | Traditional Model (Pre-2019) | MAH Model (Post-2019) |
|---|---|---|
| Manufacturing Requirement | Tied to license; must own or co-own factory | Fully separable; outsource to CMO |
| Time to Market (Phase I to NDA) | 5–8 years | 3–5 years (30–40% faster) |
| Initial CapEx Requirement | High (RMB 100M+ for standard facility) | Low (RMB 5–10M for compliance & sponsorship) |
| Risk Exposure | Full supply chain & operational risk | Operational risk transferred to CMO |
| R&D Focus | Diluted by manufacturing demands | Preserved for core science |
Decision Framework: If your drug is in early clinical trials (Phase I/II) and you want to preserve capital for R&D, choose the 1.0 Model — Delegate full manufacturing to a local CMO while retaining MAH status. If your drug is already approved in the US/EU and you need a fast China launch, choose the 2.0 Model — Apply for an import drug license with a committed MAH agent relationship, leveraging existing bridging data to bypass local clinical trials where possible.
Critical Compliance Pathways for Foreign Entities
The 国家药监局 (National Medical Products Administration, guójiā yàojiān jú) now permits foreign companies to directly apply as the MAH. However, there is a key operational nuance: an overseas MAH must designate a legal entity within China to serve as its regulatory agent (代理人). This agent shares joint liability for the drug’s safety and efficacy. The 2022 Regulations on the Implementation of the Drug Administration Law clarified this relationship, making the agent responsible for pharmacovigilance (PV), adverse drug reaction (ADR) reporting, and recall coordination.
For foreign biotechs without a China entity, the fastest pathway is to establish a 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè) specifically to serve as the MAH sponsor. This subsidiary holds the MAH license while contracting manufacturing and logistics. The WFOE structure affords maximum control over IP, pricing, and clinical data. Alternatively, a foreign company may partner with a Chinese contract research and manufacturing organization (CRMO) that can serve as the agent under a services agreement — though this model introduces additional liability risks.
Three Strategic Pitfalls to Avoid
Real Numbers: Market Impact and Timeline
The economic advantage of the MAH system is measurable. Average reduction in CapEx for a foreign biotech entering China: RMB 150–300 million compared to building a greenfield facility. The contract manufacturing (CMO) market linked directly to the MAH pathway reached RMB 210 billion in 2023, growing at a compound annual growth rate (CAGR) of roughly 18% since 2019. WuXi Biologics reported a 52% year-over-year increase in MAH-related project inquiries in 2023, indicating intense demand from exactly this type of asset-light entrant.
For a Phase III-ready asset, the MAH model can save 18–24 months versus the traditional route of building a manufacturing facility from scratch. In a therapeutic area like oncology or neurology, where the market window is tightly defined by patent exclusivity, this difference often determines the viability of the entire China strategy.
Frequently Asked Questions
Can I own the MAH directly as a US company?
Yes, but you must designate a legal entity in China as your agent (代理人) for regulatory communication and joint liability. Most foreign biotechs establish a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) for this purpose.
How long does an MAH transfer take?
If you need to transfer your MAH from one manufacturer to another (e.g., switching CMOs), the standard NMPA review period is 6–12 months, provided the new site holds the relevant GMP certification. Plan this transition carefully to avoid product supply gaps.
Can I switch CMOs after approval?
Yes, but the CMO must fall under the same type of GMP certification. Substantial changes — such as switching from a local to an imported API source — require a supplemental application to the NMPA and may trigger an additional review cycle of 3–6 months.
Does the MAH system work for biologics?
Yes, but biologics require a Level 2 Biosafety (P2) compliant facility. Specific technical requirements for MAH + CMO arrangements covering biologics were clarified in a 2022 NMPA notice. Expect stricter audit requirements and a longer review cycle for biosimilar or innovative biologic applications.
What happens if my CMO fails a GMP inspection?
The MAH bears primary responsibility. You will receive a Warning Letter and potentially a production halt order. It is critical to name the CMO in a supporting role in your application and maintain contractual language that forces the CMO to cooperate fully with regulator investigations.
Next Steps
- Evaluate your asset lifecycle: Determine whether the MAH model (asset-light) or a full local operation best fits your pipeline stage and capital position. Read our guide on biotech entry strategy for China.
- Perform CMO due diligence: Not all CMOs are equal in quality or regulatory compliance history. We recommend you review our CMO selection framework before signing any agreements.
- Establish your local agent entity: Set up your WFOE or designate a compliance-qualified third-party agent. Our WFOE registration guide covers the timeline, costs, and necessary local partnerships.
— China Gateway 360 —
Remote China market entry support, built around execution.
